These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 8652743)
1. Direct comparison of bromodeoxyuridine and Ki-67 labelling indices in human tumours. Wilson GD; Saunders MI; Dische S; Daley FM; Robinson BM; Martindale CA; Joiner B; Richman PI Cell Prolif; 1996 Mar; 29(3):141-52. PubMed ID: 8652743 [TBL] [Abstract][Full Text] [Related]
2. Analysis of response to radiation therapy of patients with cervical adenocarcinoma compared with squamous cell carcinoma. MIB-1 and PC10 labeling indices. Oka K; Nakano T; Hoshi T Cancer; 1996 Jun; 77(11):2280-5. PubMed ID: 8635096 [TBL] [Abstract][Full Text] [Related]
3. A comparison of proliferation markers (BrdUrd, Ki-67, PCNA) determined at each cell position in the crypts of normal human colonic mucosa. Bromley M; Rew D; Becciolini A; Balzi M; Chadwick C; Hewitt D; Li YQ; Potten CS Eur J Histochem; 1996; 40(2):89-100. PubMed ID: 8839702 [TBL] [Abstract][Full Text] [Related]
6. The labelling index of human and mouse tumours assessed by bromodeoxyuridine staining in vitro and in vivo and flow cytometry. Wilson GD; McNally NJ; Dunphy E; Kärcher H; Pfragner R Cytometry; 1985 Nov; 6(6):641-7. PubMed ID: 4064843 [TBL] [Abstract][Full Text] [Related]
7. Immunocytochemical detection of cell proliferation-related antigens in cytologic smears of human malignant neoplasms using PC10, reactive with proliferating cell nuclear antigen, and Ki-67. A comparative study. Pelosi G; Bresaola E; Manfrin E; Rodella S; Schiavon I; Iannucci A Arch Pathol Lab Med; 1994 May; 118(5):510-6. PubMed ID: 7910728 [TBL] [Abstract][Full Text] [Related]
8. Immunoreactivity of proliferating cell nuclear antigen compared with bromodeoxyuridine incorporation in normal and neoplastic rat tissue. Wijsman JH; Van Dierendonck JH; Keijzer R; van de Velde CJ; Cornelisse CJ J Pathol; 1992 Sep; 168(1):75-83. PubMed ID: 1360499 [TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical detection of proliferative cells. Mokrý J; Nĕmecek S Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove; 1995; 38(3):107-13. PubMed ID: 8685626 [TBL] [Abstract][Full Text] [Related]
10. The lack of correlation between proliferation (Ki-67, PCNA, LI, Tpot), p53 expression and radiosensitivity for head and neck cancers. Björk-Eriksson T; West CM; Cvetskovska E; Svensson M; Karlsson E; Magnusson B; Slevin NJ; Edström S; Mercke C Br J Cancer; 1999 Jul; 80(9):1400-4. PubMed ID: 10424742 [TBL] [Abstract][Full Text] [Related]
11. Heterogeneity in proliferation markers in colorectal cancer. Kressner U; Lindmark G; Gerdin B; Pahlman L; Glimelius B Anticancer Res; 1995; 15(6B):2755-61. PubMed ID: 8669859 [TBL] [Abstract][Full Text] [Related]
12. Methodological aspects of using immunohistochemical cell proliferation biomarkers in colorectal carcinoma chemoprevention. Risio M J Cell Biochem Suppl; 1994; 19():61-7. PubMed ID: 7823607 [TBL] [Abstract][Full Text] [Related]
13. Studies with bromodeoxyuridine in head and neck cancer and accelerated radiotherapy. Wilson GD; Dische S; Saunders MI Radiother Oncol; 1995 Sep; 36(3):189-97. PubMed ID: 8532905 [TBL] [Abstract][Full Text] [Related]
14. A technique for automatic/interactive assessment of the proliferating fraction of neoplastic cells in solid tumors. A methodological study on the Ki-67 immunoreactive cells in human mammary carcinomas, including a comparison with the results of conventional S-phase fraction assessments by means of DNA cytometry. Parrado C; Falkmer UG; Höög A; Falkmer S; Ahrens O; Rius F; Grimelius L Gen Diagn Pathol; 1996 Mar; 141(3-4):215-27. PubMed ID: 8705786 [TBL] [Abstract][Full Text] [Related]
15. Correlation between iododeoxyuridine and MIB-1 labelling index in gastric carcinoma and adjacent normal gastric tissue. Schipper DL; Wagenmans MJ; Peters WH; Wobbes T; Wagener DJ Anticancer Res; 2000; 20(2A):707-14. PubMed ID: 10810344 [TBL] [Abstract][Full Text] [Related]
16. Simultaneous triple staining for hypoxia, proliferation, and DNA content in murine tumours. Webster L; Hodgkiss RJ; Wilson GD Cytometry; 1995 Dec; 21(4):344-51. PubMed ID: 8608732 [TBL] [Abstract][Full Text] [Related]
17. Comparison of proliferation activity in breast carcinoma by flow cytometry analysis of S-phase and quantitative analysis of MIB-1. Masood S; Bui MM; Lu L Ann Clin Lab Sci; 1998; 28(6):315-23. PubMed ID: 9846198 [TBL] [Abstract][Full Text] [Related]
18. Prognostic relevance of MIB-1 immunoreactivity, S-phase fraction, 5-bromo-2'-deoxyuridine labeling indices, and mitotic figures in gliomas. Struikmans H; Rutgers DH; Jansen GH; Dullens HF; Oosten L; Tulleken CA; van der Tweel I; Battermann JJ Radiat Oncol Investig; 1999; 7(4):243-8. PubMed ID: 10492165 [TBL] [Abstract][Full Text] [Related]
19. Kinetic heterogeneity of an experimental tumour revealed by BrdUrd incorporation and mathematical modelling. Bertuzzi A; Faretta M; Gandolfi A; Sinisgalli C; Starace G; Valoti G; Ubezio P Bull Math Biol; 2002 Mar; 64(2):355-84. PubMed ID: 11926121 [TBL] [Abstract][Full Text] [Related]
20. Analysis of cell cycle-related Ki-67 and p120 expression by flow cytometric BrdUrd-Hoechst/7AAD and immunolabeling technique. Endl E; Steinbach P; Knüchel R; Hofstädter F Cytometry; 1997 Nov; 29(3):233-41. PubMed ID: 9389440 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]